Eurazeo Completes Acquisition of Kurma Partners

Eurazeo has finalized the acquisition of the remaining shares in Kurma Partners, a French asset management company known for its focus on biotechnology and medical innovation. This follows Eurazeo’s majority acquisition of 70.6% in 2021. Kurma Partners, handling almost €600 million in assets, is a significant player in the European healthcare sector, providing crucial support to promising companies since 2009.

The acquisition aligns with Eurazeo's commitment to the healthcare sector, with assets targeted at healthcare investments reaching €3 billion by the end of 2024. Recent trade exits such as Amolyt Pharma and Emergence Therapeutics illustrate Kurma Partners' robust value creation capabilities. Eurazeo plans to sustain its support, preserving Kurma's operational independence while bolstering its investment strategy.